JPY 7,100.00
-32.00 (-0.45%)
JPY · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 2914.T is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II HyperlipidaemiaNCT00686010%change from baseline in HDL-C, Inhibition of CETP activityRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, JTT-705 300mg, JTT-705 600mg, JTT-705 900mg | Type II Hyperlipidaemia | 198 | Jan 2001actual | 2008-05-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19